
Fulgent Genetics completes acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics finalizes $56.9 million deal to expand pathology and dermatopathology capabilities with Bako Diagnostics and StrataDx Fulgent Genetics, Inc., a technology-driven company known for its strong laboratory services platform…












